EADV 2026视频特辑｜Thrasyvoulos Tzellos教授：化脓性汗腺炎的诊疗分层策略、临床痛点与领域新突破

Thrasyvoulos Tzellos 教授围绕 2026 欧洲皮肤病与性病学会（EADV）大会最新研究数据，系统解读化脓性汗腺炎（HS）的临床治疗决策逻辑、领域核心未满足需求与前沿研发进展。内容涵盖生物制剂与手术的联合诊疗策略、免疫纤维化的疾病认知更新，以及白介素 17 抑制剂、JAK 抑制剂、新型靶点药物的最新研究成果，全面呈现 HS 诊疗领域的前沿动态与未来发展方向。

 

Professor Thrasyvoulos Tzellos systematically interprets the clinical treatment decision-making logic, core unmet needs in the field, and cutting-edge research and development progress of hidradenitis suppurativa (HS) based on the latest research data from the 2026 Congress of the European Academy of Dermatology and Venereology (EADV).

The content covers the combined diagnosis and treatment strategy of biologics and surgery, the updated understanding of immunofibrosis in the disease, as well as the latest research findings of IL-17 inhibitors, JAK inhibitors and novel targeted therapies, comprehensively presenting the cutting-edge trends and future development directions in the field of HS diagnosis and treatment.